Warner Chilcott Announces FDA Approval of DELZICOL
Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The product will be marketed as DELZICOL™ (mesalamine) 400 mg delayed-release capsules. The Company anticipates that it will commercially launch DELZICOL in March 2013.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.